(NYSE: EBS) Emergent Biosolutions's forecast annual revenue growth rate of -8.51% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.29%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 11.76%.
Emergent Biosolutions's revenue in 2025 is $965,400,000.On average, 2 Wall Street analysts forecast EBS's revenue for 2025 to be $43,948,213,744, with the lowest EBS revenue forecast at $42,939,188,940, and the highest EBS revenue forecast at $44,957,238,548. On average, 2 Wall Street analysts forecast EBS's revenue for 2026 to be $49,866,939,389, with the lowest EBS revenue forecast at $37,042,988,593, and the highest EBS revenue forecast at $62,690,890,185.
In 2027, EBS is forecast to generate $34,747,579,289 in revenue, with the lowest revenue forecast at $34,747,579,289 and the highest revenue forecast at $34,747,579,289.